Institutional equity research analysts covering Cartesian Therapeutics (NASDAQ: RNAC) project an average 12-month consensus price target of approximately $32.60 per share, with individual forecasts ranging from a low target of $16.00 up to a bull-case high of $44.00. These projections reflect high optimism regarding the clinical advancement of its proprietary cell therapies, though actual stock performance remains dependent on successful trial readouts, regulatory milestones, and broader biotechnology market sentiment.